Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 6/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.36 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.36 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23243983 | 0.87 | TK1 (0.41) | — | |
| SCHEMBL20393996 | 0.86 | NT5E (0.38) | P2RY6P2RY2P2RY4P2RY12SLC28A1 | |
| SCHEMBL20393999 | 0.86 | NT5E (0.38) | P2RY6P2RY2P2RY4P2RY12SLC28A1 | |
| SCHEMBL1097719 | 0.86 | SLC28A1 (0.43) | P2RY6P2RY2P2RY4P2RY12SLC28A1 | |
| SCHEMBL18049482 | 0.85 | P2RY6 (0.40) | P2RY6P2RY2P2RY4P2RY12SLC28A1 | |
| SCHEMBL18049469 | 0.85 | P2RY6 (0.40) | P2RY6P2RY2P2RY4P2RY12SLC28A1 | |
| SCHEMBL25404146 | 0.85 | P2RY6 (0.40) | P2RY6P2RY2P2RY4P2RY12SLC28A1 | |
| SCHEMBL25400398 | 0.83 | NT5E (0.39) | P2RY6P2RY2P2RY4P2RY12SLC28A1 | |
| SCHEMBL13835027 | 0.81 | NT5E (0.40) | P2RY6P2RY2P2RY4P2RY12SLC28A1 | |
| SCHEMBL24066395 | 0.81 | P2RY6 (0.39) | P2RY6P2RY2P2RY4P2RY12SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2026-04-16 | — | — | US | disclosed |
| CN-112105625-B | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | 赛诺菲 | 2024-12-31 | — | — | CN | disclosed |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2024-11-14 | — | — | US | disclosed |
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | SANOFI (FR) | 2024-02-13 | — | — | US | disclosed |
| US-20220372063-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2022-11-24 | — | — | US | disclosed |
| EP-4025582-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2022-07-13 | — | — | EP | disclosed |
| CN-114728999-A | Oligonucleotides containing nucleotide analogs | 赛诺菲 | 2022-07-08 | — | — | CN | disclosed |
| US-20210115075-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI (FR) | 2021-04-22 | — | — | US | disclosed |
| WO-2021044004-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2021-03-11 | — | — | WO | disclosed |
| EP-3762395-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | Sanofi (FR) | 2021-01-13 | — | — | EP | disclosed |
| CN-112105625-A | Nucleotide precursors, nucleotide analogs, and oligomeric compounds containing the same | 赛诺菲 | 2020-12-18 | — | — | CN | disclosed |
| WO-2019170731-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI (FR) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | RNMT, RRM2B, RRM2 | P2RY6 1244/4885P2RY2 1444/4885P2RY4 1792/4885 |
| US-20210115075-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, RRM2B, RRM2 | P2RY6 1244/4885P2RY2 1444/4885P2RY4 1792/4885 |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | NSUN2, NSUN3, SNRPA | P2RY6 2103/4885P2RY2 1252/4885P2RY4 2512/4885 |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, NSUN2, ADAR | P2RY6 1665/4885P2RY2 1382/4885P2RY4 1745/4885 |
| US-20220372063-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | DCLRE1B, UPF1, IGF2BP1 | P2RY6 4042/4885P2RY2 3960/4885P2RY4 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.